Celero Ventures

Celero Ventures is an early-stage venture capital firm based in London, focused on backing software-driven health innovations and adjacent technology categories. The firm operates in the active London early-stage ecosystem and has built a portfolio that includes companies like the acoustic monitoring startup Auryx, reflecting an interest in technology that uses novel signals to address concrete clinical or care problems.

The thesis is centered on AI in healthcare and digital health, with particular interest in software-driven products that bring new data or new automation into clinical and care settings. That includes acoustic and sensor-driven monitoring, AI applications in diagnostics and decision support, virtual care platforms, healthcare operations software, and tools that combine novel data sources with machine learning. The firm tends to favor technical founding teams with a clear scientific or engineering wedge, rather than thin software layers.

Investments are at Pre-Seed and Seed with checks of roughly two hundred fifty thousand to one million dollars. Geographic focus is the United Kingdom with selective activity across Europe. Celero is comfortable leading or co-leading at the earliest stages and participating in seed rounds alongside larger UK and European investors as portfolio companies progress.

The team is small and built around investing partners with backgrounds in early-stage technology and healthcare. Founders should expect engagement that reflects a hands-on early-stage investor, including practical conversations about clinical evidence strategy, regulatory pathway for AI software in health, and the realities of going to market with new monitoring or diagnostic technologies.

The practical value of Celero is being a credible UK lead for technical founders building software-driven healthcare innovations who need a partner that takes their technology seriously. Portfolio companies benefit from introductions across the UK clinical and innovation ecosystem, including NHS pilot opportunities, follow-on investors in the UK and Europe, and operator advisors with experience in regulated medical software. The trade-off is that check sizes are modest, and most portfolio companies will need to bring in larger leads at Series A. The fit is strongest for technical founders building software-driven, often sensor-anchored, healthcare products in the UK and Europe at Pre-Seed or Seed, and weaker for capital-intensive medical device or therapeutics businesses where Celero’s stage and check size do not match the funding curve.